Main Article Content
The study aims to compare, contrast, and assess the effects of blood thinners Apixaban and Rivaroxaban upon stroke and clot risk in patients with heart disease and arrhythmia who used blood thinners. Using Danish national registries, apixaban or rivaroxaban were administered to patients who had just been diagnosed with AF. Based on the institution's preferences for the kind of NOAC— expressed as a proportion of the 20 AF patients who started taking rivaroxaban in the facility before—patients were divided into groups regardless of their current medical regimens. A useful variable was the NOAC facility choice. Higher rivaroxaban facility selection did not increase stroke/thromboembolism, Myocardial infarction, often known as overall mortality (P-trend=0.06, P-trend=0.65, or P-trend=0.89). Rivaroxaban exhibited a lower relative risk than apixaban when we employed the instrumental variable to examine the association between NOAC selection and serious bleeding (1.89; 95 percent confidence interval: 1.06-2.72). In a group of individuals with atrial fibrillation, it was discovered through the use of instrumental variable estimates that rivaroxaban carried a greater risk of serious bleeding than apixaban (AF). In the first analyses, no discernible correlations to other results were found.